Related Experiment Video
Updated: Nov 27, 2025
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
10.2K
Personalized warfarin treatment based on the PITX2 single nucleotide polymorphism rs6843082
Tianhua Liu1, Hongman Huang1, Xinbing Liu1
1Department of Cardiology, Shidong Hospital Shanghai 200000, China.
International Journal of Clinical and Experimental Pathology
|December 7, 2020
Summary
The PITX2 rs6843082 single nucleotide polymorphism influences warfarin efficacy and adverse reactions in atrial fibrillation and hypertension patients. Genotyping this SNP may personalize warfarin treatment, improving outcomes and reducing bleeding risks.
Area of Science:
- Pharmacogenomics
- Cardiovascular Medicine
- Genetics
Background:
- Warfarin is a critical anticoagulant for atrial fibrillation and hypertension.
- Individual variability in warfarin response necessitates personalized treatment approaches.
- The PITX2 gene rs6843082 polymorphism is a potential factor influencing drug metabolism and efficacy.
Purpose of the Study:
- To investigate the impact of the PITX2 gene rs6843082 single nucleotide polymorphism (SNP) on warfarin efficacy and adverse reactions.
- To establish a theoretical foundation for individualized warfarin therapy in patients with atrial fibrillation and hypertension.
Main Methods:
- Collected data from 97 patients with atrial fibrillation and hypertension.
- Utilized PCR and SNP genotyping to determine rs6843082 genotypes (PITX2).
- Compared warfarin efficacy and adverse event incidence across different genotypes.
Main Results:
- Significant differences in time to therapeutic warfarin range and maintenance dose were observed between GG, GA, and AA genotypes.
- The AA genotype group exhibited a higher probability of bleeding events compared to GG and GA groups.
- Left ventricular ejection fraction was reduced in the AA group, and mortality rates varied across genotypes.
Conclusions:
- The rs6843082 SNP in the PITX2 gene significantly affects warfarin dose response in patients with atrial fibrillation and hypertension.
- Pre-treatment genotyping for rs6843082 can optimize warfarin treatment and minimize bleeding risk.
- This finding supports the implementation of pharmacogenetic testing for personalized warfarin management.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
131
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
131
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.7K
01:05Single Nucleotide Polymorphisms-SNPs
17.4K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
17.4K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
878
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
878
01:29Therapeutic Drug Monitoring: Affecting Factors
93
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
93
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.3K